ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1909

Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Alper van Sijl1, Mamas Mamas2, Mark Lunt3,4, . BSRBR Control Centre Consortium3, Kath Watson5, Deborah P. Symmons3,6 and Kimme L. Hyrich7, 1Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2Manchester Heart Centre, Manchester Royal Infirmary, Oxford Road, Manchester, UK; Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 5Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 6Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 7Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic drugs, Cardiovascular disease, Heart disease, rheumatoid arthritis (RA) and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy IV: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Cardiovascular and Other Systems

Session Type: Abstract Submissions (ACR)

Background/Purpose Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease compared to the general population, with an increased incidence of congestive heart failure (CHF) possibly mediated by chronic inflammation. Anti-tumour necrosis factor (TNFi) drugs might reduce the incidence of new CHF by supressing inflammation. However, TNFi are associated with a worsening of existing CHF. The aim of this analysis was to compare the incidence of CHF in subjects with RA treated with TNFi to that in those receiving non-biologic drugs (nbDMARDs).

Methods Patients with a physician diagnosis of RA enrolled in the British Society for Rheumatology Biologics Register, a national prospective cohort study established in 2001 to monitor the long-term safety of TNFi. Potential CHF events were verified according to Framingham criteria by a cardiologist from death certificates and from clinical follow-up forms of consultants. New CHF which occurred within 6 months after another cardiac event (eg. myocardial infarction) was excluded. Risk of CHF was compared between the two cohorts using a Cox regression model, propensity scores adjusted. Subjects were censored at first episode of CHF, death, first missed dose of TNFi + 180 days, last returned clinician follow-up or 31/01/2014, whichever came first.

Results A total of 87 validated first CHFs were analysed: 48 in 3,662 nbDMARD subjects and 39 in 12,397 TNFi-exposed subjects. After adjustment for differences in baseline characteristics, the hazard ratio (95%-confidence interval) of CHF in patients on TNFi compared to nbDMARD was: 0.31 (0.18-0.52). Similar results were found for analysis limited to first TNFi only and in patients without prior history of ischaemic heart disease.

Conclusion No increased risk of CHF was observed in those patients selected for TNFi therapy compared to those receiving nbDMARD therapy. A reduced risk of CHF was noted in patients treated with TNFi.

Table. Association between exposure to TNFi and development of first CHF

 

nbDMARD (n=3662)

TNFi (n=12397)

Years of follow-up per subject, median (IQR)

5.0 (2.5-7.7)

5.1 (1.9-8.0)

 

 

 

Person-years of exposure, pyrs

18 698

62 244

 

 

 

Number of verified CHFs, n (%)

48 (1.31)

39 (0.31)

 

 

 

Crude incidence rate of verified CHFs per

10 000 person-years (95%-confidence interval)

25.67 (19.53-34.40)

6.27 (4.58-8.58)

 

 

 

Risk of CHF between nbDMARD and TNFi

 

 

–          Unadjusted HR (95%-CI)

Referent

0.24 (0.16-0.37)

–          Age- and gender adjusted HR (95%-CI)

Referent

0.47 (0.30-0.72)

–          PD-adjusted HR (95%-CI)

Referent

0.25 (0.14-0.44)

Fully adjusted model by propensity score (PD) consisting of age, gender, DAS28, disease duration, HAQ, steroid use, NSAIDs, COXIBs, hypertension, diabetes mellitus, angina pectoris, myocardial infarction, smoking history and use of statins, antiplatelets, ACE-inhibitors, warfarin and digoxin.


Disclosure:

A. van Sijl,
None;

M. Mamas,
None;

M. Lunt,
None;

BSRBR Control Centre Consortium,
None;

K. Watson,
None;

D. P. Symmons,
None;

K. L. Hyrich,

Pfizer Inc,

9,

Abbott Immunology Pharmaceuticals,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-congestive-heart-failure-in-subjects-with-rheumatoid-arthritis-receiving-anti-tumour-necrosis-factor-drugs-results-from-the-british-society-for-rheumatology-biologics-register-for-rheuma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology